Literature DB >> 14698484

Target evaluation processing and serum levels of nerve tissue protein S100B in patients with remitted major depression.

Detlef E Dietrich1, Ute Hauser, Marion Peters, Yuanyuan Zhang, Martin Wiesmann, Mark Hasselmann, Sebastian Rudolf, Oliver Jüngling, Holger Kirchner, Thomas F Münte, Volker Arolt, Hinderk M Emrich, Sönke Johannes, Matthias Rothermundt.   

Abstract

Selective attention processes (N2 and P3 components of event-related potentials (ERPs)) have been shown to be impaired in depressed patients but findings have been mixed. Part of this variability might be explained by neurobiological factors. ERPs (Go/Nogo paradigm) were investigated in patients with remitted major depression in relation to S100B. S100B, an astroglial protein with neuroplastic properties, has been shown to be increased in depression. Its pathophysiologic role in depression, however, is not yet sufficiently understood. Patients with increased S100B serum levels (n=6) showed a normal N2- and P3-amplitude in contrast to a reduced N2- and P3-amplitude in patients with normal S100B serum levels (n=6). These findings provide evidence of a correlation between S100B levels and attentional processes in patients with recurrent depression and further substantiate S100B's role as a marker in the course of affective disorders.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14698484     DOI: 10.1016/j.neulet.2003.09.062

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  8 in total

1.  The effects of gender and numbers of depressive episodes on serum S100B levels in patients with major depression.

Authors:  Kun Yang; Guang-Rong Xie; Yi-Qiu Hu; Fu-Qiang Mao; Lin-Yan Su
Journal:  J Neural Transm (Vienna)       Date:  2008-11-04       Impact factor: 3.575

2.  The astroglial protein S100B and visually evoked event-related potentials before and after antidepressant treatment.

Authors:  Guenter Hetzel; Olaf Moeller; Stefan Evers; Andreas Erfurth; Gerald Ponath; Volker Arolt; Matthias Rothermundt
Journal:  Psychopharmacology (Berl)       Date:  2004-08-14       Impact factor: 4.530

Review 3.  Neuropsychiatric disorders related to interferon and interleukins treatment.

Authors:  Aye Mu Myint; Markus J Schwarz; Harry W M Steinbusch; Brian E Leonard
Journal:  Metab Brain Dis       Date:  2008-12-10       Impact factor: 3.584

4.  Chronic mild stress induces fluoxetine-reversible decreases in hippocampal and cerebrospinal fluid levels of the neurotrophic factor S100B and its specific receptor.

Authors:  Han Rong; Gaohua Wang; Tiebang Liu; Huiling Wang; Qirong Wan; Senghong Weng
Journal:  Int J Mol Sci       Date:  2010-12-21       Impact factor: 5.923

Review 5.  Inflammation-driven brain and gut barrier dysfunction in stress and mood disorders.

Authors:  Ellen Doney; Alice Cadoret; Laurence Dion-Albert; Manon Lebel; Caroline Menard
Journal:  Eur J Neurosci       Date:  2021-05-17       Impact factor: 3.698

6.  Serum S100B Protein Levels in Patients with Panic Disorder: Effect of Treatment with Selective Serotonine Reuptake Inhibitors.

Authors:  Berna Cagatay Kaya; Hasan Karadag; Ozgur Oner; Aysegul Kart; Mehmet Hakan Turkcapar
Journal:  Psychiatry Investig       Date:  2014-12-12       Impact factor: 2.505

7.  Blood levels of S-100 calcium-binding protein B, high-sensitivity C-reactive protein, and interleukin-6 for changes in depressive symptom severity after coronary artery bypass grafting: prospective cohort nested within a randomized, controlled trial.

Authors:  Daniel M Pearlman; Jeremiah R Brown; Todd A MacKenzie; Felix Hernandez; Souhel Najjar
Journal:  PLoS One       Date:  2014-10-20       Impact factor: 3.240

8.  Serum S100B levels in patients with depression.

Authors:  Parul Arora; Rajesh Sagar; Manju Mehta; Pooja Pallavi; Subhadra Sharma; Asok Kumar Mukhopadhyay
Journal:  Indian J Psychiatry       Date:  2019 Jan-Feb       Impact factor: 1.759

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.